Evidence for dual effects of DNA-reactive bile acid derivatives (Bamets) on hepatitis B virus life cycle in an in vitro replicative system

Antiviral Chemistry and Chemotherapy

Volumn 13, Issue 6, 2002, Pages 371-380

  Romero, Marta R ^b   Martinez Diez, Maria C ^b   Larena, Monica G ^b   Macias, Rocio I R ^b   Dominguez, Mercedes ^a   Garcia Monzon, Carmelo ^b   Serrano, Maria A ^b   Marin, Jose J G ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b NONE

Author keywords

Cisplatin; Drug; Liver; Targeting; Transport; Ursodeoxycholic acid

Indexed keywords

BILE ACID; CISPLATIN DERIVATIVE; DNA FRAGMENT; FORMAZAN; GLYCOCHOLIC ACID; PLATINUM; URSODEOXYCHOLIC ACID DERIVATIVE; VIRUS DNA; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DNA REPLICATION; DRUG CONCENTRATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOUTHERN BLOTTING; VIRION; VIRUS REPLICATION;

EID: 0038749441     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020201300605     Document Type: Article

References (43)

1. Acs G, Sells MA, Purcell RH, Price P, Engle R, Shapiro M & Popper H (1987) Hepatitis B virus produced by transfected HepG2 cells causes hepatitis in chimpanzees. Proceedings of the National Academy of Sciences USA 84:4641-4644.
2. Aden DP, Fogel A, Plotkin S, Damjanov I & Knowles BB (1979) Controlled synthesis of HBsAg in different human liver carcinoma-derived cell-line. Nature 282:615-616.
3. Bartholomeusz A & Locarnini S (2001) Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 34:432-435.
4. Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H & Marin JJG (2002) Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Molecular Pharmacology 61:853-860.
5. Chouteau, P, Le Seyec J, Saulier-Le Drean B, Cannie I, Brissot P, Lescoat G, Guguen-Guillouzo C & Gripon P (2001) Inhibition of hepatitis B virus production associated with high levels intracellular viral DNA intermediates in iron-depleted HepG2 2.2.15 cells. Journal of Hepatology 34:108-113.
6. Copeland J, Skelly J, Mann GF, Howard CR & Zucherman AJ (1980) Hepatitis B surface antigen production as a growth cycle-related terminal event in PCL/PRF/5 hepatoma cells. Journal of Medical Virology 5:257-264.
7. Criado JJ, Macias RIR, Medarde M, Monte MJ, Serrano MA & Marin JJG (1997) Synthesis and characterization of the new cytostatic complex cis-diammineplatinum(II) chlorocholylglycinate. Bioconjugate Chemistry 8:453-458.
8. Criado JJ, Domínguez MF, Medarde M, Fernández ER, Macias RIR & Marin JJG (2000) Structural characterization, kinetic studies, and in vitro biological activity of new cis-diamminebis-cholylglycinate (O,O′) Pt(II) and cis-diamminebis-ursodeoxycholate(O,O′) Pt(II) complexes. Bioconjugate Chemistry 11:167-174.
9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C & Rubin M (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 333:1657-1661.
10. Dominguez MF, Macias RIR, Izco-Basurko I, de la Fuente A, Pascual MJ, Criado JM, Monte MJ, Yajeya J & Marin JJG (2001) Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. Journal of Pharmacology & Experimental Therapeutics 297:1106-1112.
11. Donaldson KL, Goolsby GL & Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. International Journal of Cancer 57:847-855.
12. Fang CT, Nath N, Pielech M & Dodd RY (1981) A modified technique for the detection of hepatitis B virus-specific DNA polymerase. Journal of Virology Methods 2:349-356.
13. Fautz R, Husein B & Hechenberger C (1991) Application of the Neutral Red assay (NR assay) to monolayer cultures of primary hepatocytes. Rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutation Research 235:173-179.
14. Guidotti LG, Martinez V, Loh Y-T, Rogler CE & Chisari FV (1994) Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. Journal of Virology 68:5469-5475.
15. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C & Jones EA (1988) Randomized, controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325.
16. Iino S (2002) Natural history of hepatitis B and C virus infections. Oncology 62:18-23.
17. Kalinina T, Riu A, Fischer L, Will H & Sterneck M (2001) A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology 34:385-394.
18. Kaneko S, Feinstone SM & Miller RH (1989) Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique. Journal of Clinical Microbiology 27:1930-1933.
19. Kock J, Theilmann L, Galle P & Schlicht HJ (1996) Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 23:405-413.
20. Kullak-Ublick GA, Beuers U & Paumgartner G (1996) Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23:1053-1060.
21. Lien J, Petcu DJ, Aldrich DL & Mason WS (1987) Initiation of termination of duck hepatitis B virus DNA synthesis during virus maturation. Journal of Virology 61:3832-3840.
22. Macias RIR, Monte MJ, El-Mir MY, Villanueva GR & Marin JJG (1998) Transport and biotransformation of the new cytostatic complex cis-diammineplatinun(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. Journal of Lipid Research 39:1792-1798.
23. Marchegiano P, Carubbi F, Tiribelli C, Amarri S, Stebel M, Lunazzi GC, Levy D & Bellentani S (1992) Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochemical & Biophysical Research Communications 183:1203-1208.
24. Marin JJG, Macias RIR, Criado JJ, Bueno A, Monte MJ & Serrano MA (1998) DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. International Journal of Cancer 78:346-352.
25. Marin JJG, Macias RIR, Monte MJ, El-Mir MY & Serrano MA (2001) Liver targeting of cisplatin-derived cytostatic drugs (Bamets) by coupling to bile acids. In Biology of Bile Acids in Health and Diseases, pp. 271-277. Edited by GP van Berge Henegouwen, D Keppler, U Leuschner, G Paumgartner and A Stiehl. Dordrech: Kluwer Academic Publishers.
26. Marion PL, Cullen JM, Azcarraga RR, Davellaar MJ & Robinson WS (1987) Experimental transmission of duck hepatitis B virus to Pekin ducks and domestic geese. Hepatology 7:724-731.
27. Markwell MAK, Haas SM, Bieber LL & Tolbert NE (1987) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anaytical Biochemistry 87:206-210.
28. Martinez-Diez MC, Larena MG, Serrano MA, Macias RIR, Izco-Basurko I & Marin JJG (2000) Relationship between DNA-reactivity and cytostatic activity of two novel bile acid-platinum derivatives, Bamet-UD2 and Bamet D3. Anticancer Research 20:3315-3322.
29. Meier PJ & Stieger B (2002) Bile salt transporters. Annual Review of Physiology 64:635-661.
30. Mendoza ME, Monte MJ, El-Mir MY, Badia MD & Marin JJG (2002) Changes in the pattern of bile acids in the nuclei of rat liver cells during hepatocarcinogenesis. Clinical Science 102:143-150.
31. Miller RH, Kaneko S, Chung CT, Girones R & Purcell RH (1989) Compact organization of the hepatitis B virus genome. Hepatology 9:322-327.
32. Molnar-Kimber KL, Summers JW & Mason WS (1984) Mapping of the cohesive overlap of duck hepatitis B virus DNA and of the site of initiation of reverse transcription. Journal of Virology 51:181-191.
33. Monte MJ, Martinez-Diez MC, El-Mir MY, Mendoza ME, Bravo P, Bach O, Marin JJG (2002) Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration. Journal of Hepatology 36:534-542.
34. Murray SM, Frieman JS, Vichery K, Lim D, Cosart YE & Whiteley RK (1991) Duck hepatitis B virus: A model to asses efficacy of disinfectants against hepadnavirus infectivity. Epidemiology Infection 106:435-443.
35. Ozer A, Khaoustov VI, Mearns M, Lewis DE, Genta RM, Darlington GJ & Yoffe B (1996) Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology 110:1519-1528.
36. Pugh JC & Bassendine MF (1990) Molecular biology of hepadnavirus replication. British Medical Bulletin 46:329-353.
37. Schalm SW, Deman RA, Heijtink RA & Niesters HGM (1995) New nucleoside analogues for chronic hepatitis B. Journal of Hepatology 22:52-56.
38. Sells MA, Chen ML & Acs G (1987) Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences of USA 84:1005-1009.
39. Summers J, Smith PM & Horwich AL (1990) Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. Journal of Virology 64:2819-2824.
40. Sundquist WI & Lippard SJ (1990) The coordination chemistry of platinum anticancer drugs and related compounds with DNA. Coordination Chemistry Reviews 100:293-322.
41. Trauner M & Graziadei IW (1999) Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Alimentary Pharmacology & Therapeutics 13:979-995.
42. Tuttleman JS, Pourcel C & Matsubara K (1986) Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 29:403-413.
43. Wang GH & Seeger C (1993) Novel mechanism for reverse transcription in hepatitis B viruses. Journal of Virology 67:6507-6512.